Literature DB >> 25054893

Which therapeutic approach is feasible for elderly people with glioblastoma?

Alba Fiorentino1, Mario Balducci, Silvia Chiesa.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 25054893      PMCID： PMC6128192          DOI： 10.2217/cns.13.51

Source DB:  PubMed          Journal:  CNS Oncol        ISSN： 2045-0907


× No keyword cloud information.
  20 in total

1.  Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.

Authors:  Annika Malmström; Bjørn Henning Grønberg; Christine Marosi; Roger Stupp; Didier Frappaz; Henrik Schultz; Ufuk Abacioglu; Björn Tavelin; Benoit Lhermitte; Monika E Hegi; Johan Rosell; Roger Henriksson
Journal:  Lancet Oncol       Date:  2012-08-08       Impact factor: 41.316

2.  Glioblastoma therapy in the elderly: one age does not fit all.

Authors:  Phioanh Leia Nghiemphu; Timothy Cloughesy
Journal:  Lancet Oncol       Date:  2012-08-08       Impact factor: 41.316

Review 3.  Elderly patients with glioblastoma: the treatment challenge.

Authors:  Alba Fiorentino; Pasquale De Bonis; Silvia Chiesa; Mario Balducci; Vincenzo Fusco
Journal:  Expert Rev Neurother       Date:  2013-10       Impact factor: 4.618

4.  Improving prognosis of glioblastoma in the 21st century: who has benefited most?

Authors:  Yaacov Richard Lawrence; Mark V Mishra; Maria Werner-Wasik; David W Andrews; Timothy N Showalter; Jon Glass; Xinglei Shen; Zvi Symon; Adam P Dicker
Journal:  Cancer       Date:  2011-12-16       Impact factor: 6.860

5.  High-grade glioma: elderly patients, older treatments.

Authors:  Pasquale De Bonis; Annunziato Mangiola; Angelo Pompucci; Manuela Porso; Carmelo Anile
Journal:  Expert Rev Neurother       Date:  2012-11       Impact factor: 4.618

6.  Can elderly patients with newly diagnosed glioblastoma be enrolled in radiochemotherapy trials?

Authors:  Alba Fiorentino; Mario Balducci; Pasquale De Bonis; Silvia Chiesa; Laura De Filippo; Annunziato Mangiola; Fiorenza De Rose; Rosa Autorino; Carla Rinaldi; Sergio Fersino; Barbara Diletto; Paolo Matteucci; Elisa Ciurlia; Vincenzo Fusco; Carmelo Anile; Vincenzo Valentini
Journal:  Am J Clin Oncol       Date:  2015-02       Impact factor: 2.339

7.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

Authors:  Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

8.  Do comorbidity influences acute toxicity and outcome in elderly patients with endometrial cancer treated by adjuvant radiotherapy plus brachytherapy?

Authors:  A Fiorentino; C Chiumento; V Fusco
Journal:  Clin Transl Oncol       Date:  2013-01-29       Impact factor: 3.405

9.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

10.  Concurrent and adjuvant temozolomide-based chemoradiotherapy schedules for glioblastoma. Hypotheses based on two prospective phase II trials.

Authors:  M Balducci; A Fiorentino; P De Bonis; S Chiesa; A Mangiola; G C Mattiucci; G R D'Agostino; V Frascino; G Mantini; A R Alitto; C Colosimo; C Anile; V Valentini
Journal:  Strahlenther Onkol       Date:  2013-08-24       Impact factor: 3.621
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.